CRISPR gene editing player Editas Medicine just set the terms for its forthcoming IPO, according to a new regulatory filing.
The Cambridge-based startup will offer 5.9 million shares, priced between $16 to $18 to raise an upsized $122 million. It plans to trade on the NASDAQ under ticker symbol “EDIT.”
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
This is a relatively small fundraise, considering the fact that just five months ago it raised an impressive $120 million Series B round – with a notable backer including Bill Gates. It was founded in 2013 with a $43 million Series A.
Editas’ most advanced program, as stated in its prospectus, is its work in treating Leber Congenital Amaurosis Type 10, an inherited form of progressive blindness with no approved therapies or clinical trials in the U.S. or Europe. It plans to kick off a proof-of-concept clinical trial next year for this program.
Editas has gene editing programs underway, in partnership with Juno Therapeutics, to engineer T cell therapies for cancer. It’s interested in addressing genetic, infectious and oncologic diseases of the liver, lung, blood, eye and muscle.
The company initially filed for an IPO on January 4. The following day, it announced two new leadership appointments – with alums from Cubist Pharmaceuticals and Biogen.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
[Image courtesy of Flickr user andylepp]